Analyst Activity – FBR & Co Reiterates Buy on Alnylam Pharmaceuticals (NASDAQ:ALNY)

98

Analyst Ratings For Alnylam Pharmaceuticals (NASDAQ:ALNY)

Today, FBR & Co reiterated its Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY).

There are 7 hold ratings, 9 buy ratings on the stock.

The current consensus rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) is Buy (Score: 2.56) with a consensus target price of $65.44 per share, a potential 9.59% upside.

Some recent analyst ratings include

  • 3/20/2017-FBR & Co Reiterated Rating of Buy.
  • 2/9/2017-Needham & Company LLC Reiterated Rating of Buy.
  • 2/2/2017-Ladenburg Thalmann Financial Services initiated coverage with a Buy rating.

Dividend information for Alnylam Pharmaceuticals (NASDAQ:ALNY)

.
Recent Insider Trading Activity For Alnylam Pharmaceuticals (NASDAQ:ALNY)
Alnylam Pharmaceuticals (NASDAQ:ALNY) has insider ownership of 4.00% and institutional ownership of 88.70%.

  • On 1/25/2017 Philip A Sharp, Director, sold 15,000 with an average share price of $37.95 per share and the total transaction amounting to $569,250.00. View SEC Filing
  • On 1/18/2017 Philip A Sharp, Director, sold 15,000 with an average share price of $37.83 per share and the total transaction amounting to $567,450.00. View SEC Filing
  • On 11/30/2016 Akshay Vaishnaw, CMO, sold 29,165 with an average share price of $44.99 per share and the total transaction amounting to $1,312,133.35. View SEC Filing
  • On 10/13/2016 David E I Pyott, Director, bought 27,900 with an average share price of $37.00 per share and the total transaction amounting to $1,032,300.00. View SEC Filing
  • On 7/20/2016 John Maraganore, CEO, sold 30,151 with an average share price of $64.69 per share and the total transaction amounting to $1,950,468.19. View SEC Filing
  • On 4/20/2016 John Maraganore, CEO, sold 30,151 with an average share price of $67.46 per share and the total transaction amounting to $2,033,986.46. View SEC Filing
  • On 3/9/2016 Michael W Bonney, Director, bought 2,000 with an average share price of $58.36 per share and the total transaction amounting to $116,720.00. View SEC Filing

About Alnylam Pharmaceuticals (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company’s lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).

Recent Trading Activity for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Shares of Alnylam Pharmaceuticals closed the previous trading session at 59.71 up +4.46 8.07% with 1,845,804 shares trading hands.

An ad to help with our costs